Compare GSK plc (GSK) vs Millicom International Cellular S.A. Common Stock (TIGO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Millicom International Cellular S.A. Common Stock — how do they compare? GSK plc trades at $48.54 (market cap $92.78B), while Millicom International Cellular S.A. Common Stock trades at $80.27 (market cap $13.34B). The key difference: GSK plc is far larger — about 7× Millicom International Cellular S.A. Common Stock's market cap, and GSK plc pays the higher dividend (3.92%). Which is the better fit depends on your goals — on Pluang, investors hold GSK plc for 93 Days and Millicom International Cellular S.A. Common Stock for 0 Days on average.
| GSK | TIGO | |
|---|---|---|
Market Cap | $92.78B | $13.34B |
Volume | 5,756,402 | 1,586,684 |
Sector | Health | Media |
52-Week High | $61.18 | $104.31 |
52-Week Low | $43.24 | $45.81 |
Typical Hold Time | 93 Days | 0 Days |
Enterprise Value | $112.77B | $24.38B |
Dividend Yield | 3.92% | 3.77% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $47.87, up 2.02% today, with a bearish technical signal despite recent earnings beats. The company shows strong profitability with 72.73% gross margins and 14.52% net income margin, supported by consistent revenue growth from $32.67B in 2025. Recent developments include a $750M cancer therapy acquisition and strategic focus on oncology expansion.
GSK presents a mixed outlook with solid fundamentals and strategic pipeline investments offset by technical weakness and patent cliff concerns. The stock offers value at 14.84 P/E but faces execution risks in oncology growth and HIV patent expirations. Analyst consensus leans cautious with 55% hold ratings.
TIGO trades at $79.54, down 0.92% on the day, with a neutral technical signal and key support at $79. The company reported strong 2025 results with $5.82B revenue and $1.32B net income, but 2026 earnings have missed expectations in two of the last three quarters. Recent news highlights its addition to Zacks' Strong Buy list and a consistent $0.75 quarterly dividend.
The stock offers a 12.9% upside to the consensus price target of $89.78, supported by solid profitability and cash flow, but faces risks from earnings volatility and high debt. Analyst sentiment is mixed with a Hold consensus, suggesting cautious optimism amid integration challenges from recent acquisitions.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Millicom International Cellular S.A. Common Stock
Millicom International Cellular S.A. operates telecommunications and digital services under the Tigo brand across Latin America, providing mobile, fiber broadband, and pay-TV services. The company also offers mobile financial services through its Tigo Money business.
Read more on TIGO →
